TOKYO, MUNICH and BASKING RIDGE, N.J., Nov. 21, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Considering that disease-causing and disease-protecting immune cells need to be transferred from lymphatic and secondary lymphoid organs through the peripheral circulation to their sites of action in ...

OGT has launched the SureSeq Myeloid Plus panel and OGT Universal NGS Complete Workflow. OGT, a Sysmex Group company and supplier of clinical and diagnostic genomic solutions, announced the launch of ...

- Application based on results of pivotal phase 3 QuANTUM-R study of quizartinib in patients with relapsed/refractory FLT3-ITD AML and follows recent Breakthrough Therapy designation received from the ...